HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates

The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in phase I clinical trials. To enhance the capacity of the NYVAC vector to trigger broad humoral responses and a more balanced activation of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: García-Arriaza, Juan, Perdiguero, Beatriz, Heeney, Jonathan L., Seaman, Michael S., Montefiori, David C., Yates, Nicole L., Tomaras, Georgia D., Ferrari, Guido, Foulds, Kathryn E., Roederer, Mario, Self, Steven G., Borate, Bhavesh, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, Jim, Barnett, Susan W., Burke, Brian, Cristillo, Anthony D., Weiss, Deborah E., Lee, Carter, Kibler, Karen V., Jacobs, Bertram L., Wagner, Ralf, Ding, Song, Pantaleo, Giuseppe, Esteban, Mariano
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2017
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5391471/
https://ncbi.nlm.nih.gov/pubmed/28179536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02182-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados